Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 13, 2010
Last updated: March 14, 2013
Last verified: March 2013

The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy adults aged 18 to 45 years in China.

Condition Intervention Phase
Rotavirus Gastroenteritis
Biological: Rotarix ™
Biological: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Adults

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of each solicited symptom [ Time Frame: Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Occurrence of unsolicited adverse events [ Time Frame: Within 31 days (Day 0 - Day 30) after the vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events [ Time Frame: Throughout the study period following the vaccine dose ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: March 2010
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rotarix Group
Subjects will receive Rotarix™.
Biological: Rotarix ™
Oral, single dose
Placebo Comparator: Placebo Group
Subjects will receive placebo.
Biological: Placebo
Oral, single dose


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female subject of Chinese origin, 18 years to 45 years inclusive of age at the time of the vaccination.
  • Written informed consent obtained from the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Female subjects of non-childbearing potential may be enrolled in the study.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of vaccination.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests.
  • Any clinically significant history of chronic gastrointestinal disease including uncorrected congenital malformation of gastrointestinal tract that would predispose for Intusussception.
  • Gastroenteritis within 7 days preceding the study vaccine or placebo administration.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. Planned administration/ administration of a vaccine not foreseen by the study protocol within 14 days of the study vaccine or placebo and ending 14 days after.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
  • Administration of immunoglobulins and/ or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.
  • Acute disease at the time of enrolment.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
  • History of chronic alcohol consumption and/ or drug abuse.
  Contacts and Locations
Please refer to this study by its identifier: NCT01162590

China, Guangxi
GSK Investigational Site
Liucheng County, Guangxi, China, 545200
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline Identifier: NCT01162590     History of Changes
Other Study ID Numbers: 113545
Study First Received: July 13, 2010
Last Updated: March 14, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Human Rotavirus vaccine

Additional relevant MeSH terms:
Gastrointestinal Diseases
Digestive System Diseases processed this record on April 17, 2014